Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
ViiV Healthcare extends Medicines Patent Pool licence agreement for dolutegravir to cover all lower middle-income countries
Follows announcement by majority shareholder GSK to expand graduated approach to patents and intellectual property (IP)
-
GSK announces start of a phase II study to evaluate an anti GM-CSF antibody for inflammatory hand osteoarthritis
Phase II study evaluates efficacy and safety of an investigational anti-granulocyte macrophage colony-stimulating factor monoclonal antibody
-
GSK opens new state of the art respiratory manufacturing facility in Ware, UK
GSK today opens a £56 million state of the art manufacturing facility, creating 150 new jobs in the UK,
-
GSK receives positive CHMP opinion in Europe for Strimvelis™, the first gene therapy to treat very rare disease, ADA-SCID
GSK announces a positive opinion recommending marketing authorisation for Strimvelis
-
GSK expands graduated approach to patents and intellectual property to widen access to medicines in the world’s poorest countries
GSK has a deep commitment to improving healthcare by developing innovative new medicines and widening access to them around the world.
-
GSK receives marketing authorisation for Nucala® (mepolizumab) in Japan
The Japanese Ministry of Health, Labour and Welfare has granted approval for Nucala® (mepolizumab) as a treatment for bronchial asthma.
-
Sir Andrew Witty to retire from GSK in March 2017
GSK plc today announced that Sir Andrew Witty, CEO, has indicated to the Board his intention to retire from the company in early 2017
-
GlaxoSmithKline plc (the “Company”) Directorate changes
Sir Deryck Maughan, Dr Stephanie Burns, Dr Daniel Podolsky and Hans Wijers will not stand for re-election to the Board at GSK’s AGM
-
GSK’s Advair® Diskus® achieves primary endpoint in LABA safety study of children aged 4-11 years with asthma
GSK today announced results from the paediatric ‘LABA’ (long acting beta2-agonist) safety study.
-
GSK and Miltenyi Biotec establish cell and gene therapy collaboration
Collaboration includes discovery programme for CAR-T cell-based oncology therapies
-
GSK presents data at AAAAI on efficacy of Nucala® (mepolizumab) in severe asthma patients stratified by eosinophil levels
GSK today presented results at the American Academy of Allergy, Asthma & Immunology annual meeting from a post-hoc study
-
NEJM publishes results of GSK’s long-term LABA safety study of Advair ® Diskus® in adults and adolescents with asthma
GSK today announced publication of results from the ‘LABA’ (long acting beta2-agonist) safety study, AUSTRI (SAS115359)
-
GSK presents new data on the long-term efficacy & safety of Nucala® for the treatment of severe asthma with an eosinophilic phenotype
GSK today presented new safety and efficacy data for Nucala® (mepolizumab)
-
GSK names winners of 2015 Discovery Fast Track Challenge
Six winning proposals were selected from 378 entries submitted from 21 countries across Europe and North America
-
New long-term organ damage analysis published for GSK’s Benlysta® (belimumab)
Patients with SLE are at risk of irreversible organ damage which will accrue over time and is associated with increased risk of death1.
-
ViiV Healthcare announces first phase II HIV prevention study results for investigational long-acting injectable cabotegravir
Results were presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston.
-
ViiV Healthcare announces phase II study results for first two drug, long-acting injectable regimen for HIV-1 treatment
32 week maintenance data presented at CROI showed comparable viral suppression rates between injectable regimen and three drug oral regimen
-
Four inspiring innovations which help reduce child deaths in developing countries share $1 million prize from GSK and Save the Children
Healthcare Innovation Award is a major initiative within five-year partnership to help save one million children’s lives
-
GSK’s global HIV business ViiV Healthcare completes transactions to acquire Bristol-Myers Squibb’s R&D HIV assets
ViiV Healthcare has completed two previously announced transactions with Bristol-Myers Squibb
-
Results announcement for the fourth quarter 2015
GSK delivers further progress with 2015 sales of £24 billion (+6%), core EPS 75.7p (-15%) and total EPS 174.3p, +>100% CER 2016
